Overview

Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery

Status:
Withdrawn
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue, and failure to surgically remove a cancer-affected lymph node or residual cancer at the surgical margin reduces a patient's chance of survival. Moreover, damage to adjacent normal tissue during surgery can result in significant morbidity. The investigators hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time as they operate. This is a safety study to assess the safety of BLZ-100 in patients with soft tissue sarcoma undergoing surgery.
Phase:
Phase 1
Details
Lead Sponsor:
Blaze Bioscience Inc.
Collaborator:
National Cancer Institute (NCI)